Long-term efficacy of a novel, once-daily triple NRTI regimen

Long-term treatment with a novel once-daily regimen comprising three nucleoside reverse transcriptase inhibitors (NRTIs) appears to be effective and well tolerated in patients with HIV infection, according to 144-week data from Study 934, presented at the 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention [Sydney, Australia; July 2007]. The study showed that a once-daily regimen comprising emtricitabine/tenofovir disoproxil fumarate [Truvada] and efavirenz [Sustiva] was associated with significantly higher virological suppression, and fewer discontinuations due to adverse events (AEs), at 144 weeks than a twice-daily regimen of lamivudine/zidovudine [Combivir] combined with once-daily efavirenz.